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Poster Session I S263antibody panel against TCRVb, (ii) CDR3 length spectratyping by
semi-quantitative RT-PCR, and (iii) DNA sequencing of the rear-
ranged CDR3 regions. Although these methods can detect oligoclo-
nal expansion of T cells they are costly, labor-intensive, and require
substantial amount of sample. Here, we adapted the newly-devel-
opedNanostring nCounter Analysis System to quantify gene expres-
sion of 45 TCRVb and 44 TCRVa gene families in a single non-
enzymatic reaction from a small number of T cells. Two sequence-
specific gene probes, one mRNA target sequence-specific capture
probe, and a second mRNA target sequence-specific fluorescent-la-
beled color-coded probe were produced for each of the TCR genes.
These were used to determine TCRVb and TCRVa usage based on
profiling the 99 V region families of T cells from healthy volunteers
by nCounter System and a subset of these data were validated by flow
cytometry with TCRVb-specific mAb. Subsequently, we analyzed
clinical samples obtained from 10 patients with advanced melanoma
treated with ex vivo propagated tumor infiltrating lymphocyte (TIL)
therapy. To validate this data set, the TCRVb panel analysis ob-
tained from nCounter assay of these samples agreed with CDR3
DNA sequencing data. This is the first time that digital mRNA pro-
filing for TCRVb and TCRVa has been undertaken without requir-
ing cDNA synthesis, enzymatic reactions, or mAb usage. Our
approach requires just a small amount of total RNA and at $1.40/
gene, this assay is cost-effective. It is anticipated that this approach
will be of significant interest to immunologists seeking tomanipulate
the human immune system.299
PRE-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT MINIMAL RESID-
UAL DISEASE PREDICTS POST-TRANSPLANT RELAPSE IN PEDIATRIC
ACUTE MYELOBLASTIC LEUKEMIA
Ammon, K., Cowan, M.J., Horn, B., Dvorak, C.C. Univeristy of Califor-
nia San Francisco Benioff Children’s Hospital, San Francisco, CA
Minimal residual disease (MRD) is well-established as a prognostic
factor in ALL, and multiple studies suggest that the existence of
MRD likely also portends a worse outcome in AML. Although pa-
tients with ALL appear to have very high relapse rates when trans-
planted with detectable MRD, it is not known whether molecular
remission prior to HCT for AML is important in terms of relapse
and survival, or whether morphologic remission is sufficient.
Methods:A retrospective reviewwas performed of pediatric patients
with AML undergoing myeloablative allogeneic transplants at our
center from 2000-2010. Bone marrow pathology reports, including
flow cytometry reports when available, from within 2 weeks prior
to start of conditioning were reviewed. Patients were grouped by
morphologic remission status (remission defined by blasts\ 5%)
and by MRD status. MRD was defined by the presence of $ 0.1%
blasts by flow cytometry, or positive cytogenetics with\ 5% blasts.
Event-free survival (EFS), relapse incidence (RI), and transplant-re-
lated mortality (TRM) were evaluated by Kaplan-Meier survival
analysis using Stata 11.1 (College Station, TX). The logrank test
was used to calculate p-values.
Results: 39 pediatric patients with AML underwent 42 HCTs. 24
patients are alive and well, 8 died due to disease, 5 died without re-
lapse, and 2 are alive with relapsed disease. Median follow up was
23 months (range: 1-126 months). 6 patients were not in morpho-
logic remission prior to transplant. Of 23 patients inmorphologic re-
mission with evaluable MRD, 16 were MRD negative at time of
HCT (MRD\ 0.1%). There was no difference between patients
who were MRD negative or positive in terms of gender, age at trans-
plant, donor type, stem cell source, or remission status (first remis-
sion vs. other). Comparing MRD positive patients with MRD
negative patients, the EFS was 57% vs. 81% (p 5 0.3), and TRM
was 0% vs. 13% (p 5 0.4), respectively. RI post-transplant was
43% (95% CI, 15-85%) for those patients who had evidence of
MRD, but only 6% (95% CI, 0-50%) for those who achieved
a deeper remission (p 5 0.048).
Conclusions: A pre-HCT MRD level of $ 0.1% is predictive of
post-allogeneic HCT risk of relapse in pediatric AML. This study
did not have the power to detect a statistically significant difference
in OS, EFS, or TRM based on pre-HCTMRD. Larger prospective
trials are needed to fully evaluate the implications of using pre-HCT
MRD for treatment decisions.300
THE IMPACT OF IRON OVERLOAD BEFORE TRANSPLANT AND THE
NATURAL EVOLUTION OF FERRITIN AFTER TRANSPLANT ON CHILD-
HOOD ALLOGENIC SCT
Maeba, H., Nishimura, R., Kuroda, R., Mase, S., Araki, R., Yachie, A.
Kanazawa University, Kanazawa, Ishikawa, Japan
Iron overload before hematopoietic stem cell transplantation
(HSCT) is known to be associated with non-relapse mortality, infec-
tions and sinusoidal obstructive disease (SOS). Therefore some
groups reported that iron-chelating therapy beforeHSCTmight im-
prove the outcome. After HSCTmost recipients eventually transfu-
sion independent, howevermore than half of HSCT adult long-term
survivors had above normal ferritin level and requirements of iron-
chelating therapy for such patients is still controversial. To apply
the above content mainly made by adult patients to childhood cases,
we investigated the association of iron overload with complications
and survival after allogeneic HSCT in childhood hematological dis-
orders other than thalassemia (n 5 37) using ferritin as a surrogate
marker of iron overload. We also evaluated the association between
the natural evolution of serum ferritin after HSCT and late compli-
cations (n5 33). First we performed subgroups analysis for 2 groups
by serum ferritin (F) level before HSCT (F. 1000 ng/ml, F\1000
ng/ml). There were no statistical differences in acute GVHD, infec-
tions, SOS, mortality and chronic GVHD between two groups be-
fore HSCT. Next at the time of 1-year post transplant, 3 out of 37
(8%) long-term HSCT survivors had high ferritin level. One of
them returned to normal range without iron-chelating therapy 2
years after HSCT. The two remaining patients showed persistent
hyperferritinemia (1000-3000) with/witout liver dysfuction. More
specific and sensitive methods to assess iron stores such as liver bi-
opsy should be performed in such patients, even in pediatric patients.
We concluded that high level of serum ferritin before HSCT is not
a prognostic factor in childhood patients undergoing HSCT, unlike
adult cases. Frequency of persistent hyperferritinemia in childhood
HSCT recipients wasmuch less than that in adult cases reported pre-
viously, probably due to more iron requirements in children to grow
up. The impact of iron overload and natural evolution of ferritin on
allogeneic childhood HSCT differ from adult HSCT.301
STEM CELL TRANSPLANT FOR HLH: SINGLE INSTITUTION SERIES
Allen, C., Martinez, C., Kamdar, K., Wu, M.-F., Leung, K., Kennedy-
Nasser, A., Craddock, J., Ahmed, N., Gottschalk, S., Bollard, C.,
Brenner, M., Heslop, H., McClain, K., Krance, R. Baylor College of Med-
icine, Houston, TX
Background:Hemophagocytic lymphohistiocytosis (HLH) is a syn-
drome characterized by pathologic inflammation that is almost uni-
versally fatal without immune modulating and cytotoxic
chemotherapy. Patients with familial HLH or inflammation uncon-
trolled by medical therapy require stem cell transplant.We reviewed
the clinical courses of 26 consecutive patients who underwent first
stem cell transplant for HLH to evaluate outcomes and identify clin-
ical factors associated with engraftment and survival.
Methods: Medical records of all children receiving stem cell trans-
plant for HLH at Texas Children’s Hospital (TCH) from 2000-
2010 were reviewed.
Results: The median time from onset of HLH symptoms to initial
chemotherapy was 31 days, with a median time to transplant of
148 days. Many patients had pre-transplant morbidity, with 26%
having a Lansky score 80 or less, and 50% demonstrating clinical
or lab evidence of inflammation at the start of conditioning. Re-
duced-intensity conditioning was used for 32% of the transplants.
Transplant-related morbidity included high rates of engraftment
syndrome (28%), veno-occlusive disease (24%), seizure (16%), acute
bleeding (12%), CMV reactivation (48%), EBV reactivation (12%),
adenovirus infection (28%), severe mucositis (64%) and acute graft
versus host disease (GVHD) (32%). Median time to engraftment
was 17.5 days, and there was a high rate of eventual graft failure
(21%). Day 100 survival was 81% (95% CI 64-94%), 1 year survival
was 61% (95%CI 38-77%), with a longer term survival of 58% (143
days–10 years) and most recent Lansky score . 90 for all survivors.
Conclusions: While stem cell transplant is essential for survival in
patients with familial and refractory disease HLH, it also results in
S264 Poster Session Isignificant morbidity and mortality. Factors likely include pathogen-
esis of the disease as well as prolonged prior exposure to cytotoxic
chemotherapy and immune suppression. Clinical approaches to im-
prove outcomes should optimize disease control while minimizing
toxicity before and after transplant.302
IMPROVED SURVIVAL FOLLOWING HLA-MATCHED RELATED MARROW
TRANSPLANTATION IN PEDIATRIC PATIENTS WITH SEVERE APLASTIC
ANEMIA: (A 39-YEAR RETROSPECTIVE ANALYSIS)
Burroughs, L.1,2, Woolfrey, A.1,2, Storer, B.1,3, Deeg, H.J.1,2,
Flowers, M.1,2, Martin, P.1,2, Carpenter, P.1,2, Doney, K.1,2,
Appelbaum, F.1,2, Sanders, J.1,2, Storb, R.1,2 1Fred Hutchinson Cancer
Research Center; 2University ofWashington School of Medicine; 3Univer-
sity of Washington School of Public Health
Allogeneic marrow transplantation offers curative therapy for
pediatric patients with severe aplastic anemia. Over the past 4 de-
cades, significant improvements in the long term outcome of pa-
tients treated with allogeneic marrow grafts have resulted from
progress in the prevention and treatment of graft rejection and
graft-versus-host disease (GVHD). Here we report the outcome
of 149 pediatric patients, ages 2-19 years who received HLA-
matched related marrow grafts for treatment of severe aplastic ane-
mia between 1971 and 2009. Patients were divided into 3 groups,
reflecting changes in conditioning and GVHD prophylaxis regi-
mens that occurred over time. Group 1 consisted of 100 patients
who were conditioned with Cyclophosphamide (CY; 200 mg/kg)
followed by ‘‘long’’ (102 days) Methotrexate (MTX) for GVHD
prevention. Group 2 consisted of 19 patients who received CY fol-
lowed by ‘‘short’’ (days 1, 3, 6, and 11) MTX and cyclosporine
(CSP; through day 180). Group 3 consisted of 30 patients who
were conditioned with CY and horse antithymocyte globulin
(ATG) followed by MTX and CSP for GVHD prevention. The
risk of mortality was significantly different between the 3 groups
(p\0.0001).With a median follow up of 25.2 (range, 0.3-37) years,
the 5-year survival estimates were 66% for group 1, 95% for group
2, and 100% for group 3. There was a suggestion that the risk of re-
jection was different between the 3 groups (p5 0.06) and the 3-year
estimates of graft rejection were 22%, 32%, and 12%, respectively.
The estimated probabilities of grades III-IV acute GVHD were
15% for group 1, 0% for group 2, and 3% for group 3. The
2-year estimates of chronic GVHD were 21%, 21%, and 7%,
respectively. In summary, advances in conditioning and GVHD
prophylaxis regimens as well as supportive care during the past 39
years have led to improved outcomes for pediatric patients with
severe aplastic anemia. These results strongly support the use of
allogeneic marrow transplantation for newly diagnosed pediatric
patients with severe aplastic anemia who have an HLA-matched
related donor.303
HIGH DOSE ORAL BUSULFAN AND INTRAVENOUS MELPHALAN AS
CONDITIONING THERAPY FOR AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANT (HSCT) FOR THE TREATMENT OF PEDIATRIC SOLID
TUMORS
Seber, A.1, Ginani, V.C.1, Gouveia, R.V.1, Zecchin, V.G.1, Barros, D.P.1,
Ibanez, A.1, Marconcini, J.1, Villela, N.1, Felix, O.M.W.O.1,
Simoes, P.C.1, Seixas, M.T.2, Lee, M.L.M.1, Lederman, H.M.1,
Caran, E.M.1, Macedo, C.R.1, Petrilli, A.A.1 1 Instituto de Oncologia+ TBI Focal radiation n (%)
n (%) SMN in field n (% with focal)
Cases with SMN (n56) 5 (83%) 5 (83%)
2/5 (40%)
Controls with SMN (n54) 3 (75%) 2 (50%)
1/2 (50%)Pediatrica - GRAACC - Unifesp, S~ao Paulo, SP, Brazil; 2Universidade
Federal de S~ao Paulo, S~ao Paulo, SP, Brazil
Disseminated or relapsed pediatric solid tumors usually have dis-
mal prognosis and HSCT has been used as a treatment option for
children with chemo-sensitive tumors. With modern intensive pro-
tocols, patients usually have been treated with many different drugs
and may have some degree of renal or cardiac compromise. One in-
teresting alternative would be to use two alkylating agents, busulfan
and melphalan: these drugs are not used in pediatric chemotherapy
protocols, their most important dose-limiting toxicity is marrow
suppression, and they are not toxic to the heart or kidneys. Our ob-
jective is to describe the institutional experience with autologous
HSCTwith busulfan-melphalan for the treatment of relapsed or dis-
seminated pediatric solid tumors.
Results:Nineteen patients with a median age of 11 years (2-33), 10
male, were transplanted, 12/19 with measurable disease. Diagnoses
were alveolar sarcoma (1), desmoplastic small round cell tumor
(DSRCT, 1), Wilms tumor (1), primitive neuroectodermal tumor
(PNET, 2), synovial sarcoma (2), Ewing sarcoma (6, all but 1 with
advanced disease), and stage-4 neuroblastoma (6, only 1 in 1st remis-
sion). All patients had normal marrow aspirate and biopsy prior to
transplant, including immunocytochemistry. Conditioning therapy
was busulfan 1 mg/kg/dose q 6 hours PO for 4 days on D-5 to D-
2 and melphalan 140 mg/m2 IV on D-1. Local irradiation, when
planned, was postponed for the post transplant period. Three re-
ceived bone marrow grafts and 16 peripheral blood stem cells with
target cell dose of 5x106 CD34 cells/kg. All patients engrafted
promptly and none of them had severe toxicities. One had late sinu-
soidal obstruction syndrome and one Ewing sarcoma patient had
Guillain Barre Syndrome at the time of post HSCT irradiation to
his leg. One patient with PNET, the patient with DSRCT, Wilms
tumor and 3/6 with Ewing sarcoma died of their primary disease af-
ter a median of 320 days post HSCT. The patient with alveolar sar-
coma, both with synovial sarcoma, 3 with Ewing sarcoma and all
neuroblastoma patients remain in remission and well after a median
of 10.5 months post transplant (2-119). In conclusion, busulfan-mel-
phalan was very well tolerated and 13/19 patients with advanced tu-
mors remain well and in remission. Longer follow up and a larger
number of patients are needed to define the – promising – role of
this preparative regime for high dose chemotherapy and HSCT in
the treatment of relapsed or disseminated solid tumors.304
INCIDENCE OF SECOND MALIGNANCIES (SMN) IN PEDIATRIC HEMATO-
POIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS: A REPORT COM-
PARING THOSE WITH AND WITHOUT EXOSTOSES
Danner-Koptik, K.1, Kletzel, M.1,2, Dilley, K.J.1,2 1Children’s Memorial
Hospital, Chicago, IL; 2Northwestern University, Chicago, IL
Among 650 patients transplanted in our institution between 1992
and 2008, 19 (3%) are known to have developed a SMNpost-HSCT.
We have studied HSCT survivors who developed exostoses. We
identified 27 patients with clinical and/or radiologic exostoses trans-
planted between 3/1992 and 12/2003. One patient with exostosis had
co-existent malignancies and was treated elsewhere so was excluded
from all analyses due to incomplete data and the possibility of a ge-
netic cancer susceptibility. This group was compared to controls that
were matched for gender, age within 3 years and on same side of pu-
berty, malignancy/not and HSCT type. Our aim is to describe
whether the exostosis patients have a higher risk for developing
SMNs post-HSCT. There were 6/26 (23%) with SMNs in the exos-
tosis group, 4/26 (15%) in the control group (McNemar p-valueAge at first HSCT Time HSCT to SMN A/C GvHD
Mean (range) Mean (range) %
5.5y (0.5-9.1) 11.3y (6.6-16.1) AGvHD 17%
CGvHD 50%
4.9y (1.4-9.1) 9.0y (4.3-13.3) AGvHD 75%
CGvHD 25%
